ClinVar Miner

Submissions for variant NM_000371.4(TTR):c.328C>A (p.His110Asn) (rs121918074)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 12
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Laboratory for Molecular Medicine, Partners HealthCare Personalized Medicine RCV000152541 SCV000201745 uncertain significance not specified 2017-03-30 criteria provided, single submitter clinical testing Variant classified as Uncertain Significance - Favor Benign. The p.His110Asn (al so reported as p.His90Asn) variant in TTR has been reported in 1 individual with recurrent cerebral hemorrhages, but did not segregate in an affected family mem ber (Bersano 2009). In addition, it has been reported in 1 individual with famil ial amyloidotic polyneuropathy, who also carried a second established pathogenic TTR variant (Skare 1989, Skare 1991, Skare 1994). It has also been identified b y our laboratory in 2 individuals with HCM, 1 individual with LVH, and in 1 indi vidual with DCM, who also carried 2 MYBPC3 variants sufficient to explain diseas e. This variant has also been identified in several unaffected individuals (Sara iva 1991, Alves 1997, Conners 2003, Schwarzman 2004) and in 0.12% (78/66708) of European chromosomes by the Exome Aggregation Consortium (ExAC, http://exac.broa dinstitute.org; dbSNP rs121918074). Computational prediction tools and conservat ion analysis suggest that the p.His110Asn variant may not impact the protein, th ough this information is not predictive enough to rule out pathogenicity. In sum mary, while the clinical significance of the p.His110Asn variant is uncertain, t hese data suggest that it is more likely to be benign.
Invitae RCV000014369 SCV000554847 benign Amyloidogenic transthyretin amyloidosis 2019-12-31 criteria provided, single submitter clinical testing
Ambry Genetics RCV000621211 SCV000740246 likely benign Cardiovascular phenotype 2017-10-30 criteria provided, single submitter clinical testing In silico models in agreement (benign);Subpopulation frequency in support of benign classification
CHEO Genetics Diagnostic Laboratory,Children's Hospital of Eastern Ontario RCV000770556 SCV000902004 benign Cardiomyopathy 2018-06-11 criteria provided, single submitter clinical testing
Center for Advanced Laboratory Medicine, UC San Diego Health,University of California San Diego RCV000852746 SCV000995463 likely benign Heart failure 2018-07-03 criteria provided, single submitter clinical testing
Mendelics RCV000014369 SCV001140873 uncertain significance Amyloidogenic transthyretin amyloidosis 2019-05-28 criteria provided, single submitter clinical testing
CeGaT Praxis fuer Humangenetik Tuebingen RCV000857889 SCV001151525 uncertain significance not provided 2016-06-01 criteria provided, single submitter clinical testing
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000152541 SCV001157560 uncertain significance not specified 2019-04-12 criteria provided, single submitter clinical testing The TTR c.328C>A; p.His110Asn variant (rs121918074), also published as His90Asn in the mature protein, is reported in the medical literature in an individual with recurrent cerebral hemorrhage but does not segregate with disease in the family (Bersano 2009). Additionally, the variant is reported in a family with amyloidosis who also carried a known pathogenic variant (Skare 1994). However, another variant in this codon, p.His110Asp, has been reported to segregate with disease in a large kindred with amyloid polyneuropathy (Jimenez-Zepeda 2015). The c.328C>A; p.His110Asn variant is reported in the ClinVar database with inconsistent classifications (Variation ID: 13427). The variant is reported with an allele frequency of up to 0.9% (90/10370 alleles) in the Ashkenazi Jewish population and 0.05% (155/282814 alleles) overall in the Genome Aggregation Database. The amino acid at this position is weakly conserved and computational analyses (SIFT: Damaging, PolyPhen-2: Benign) predict conflicting effects of this variant on protein structure/function. Due to conflicting information, the clinical significance of the variant is uncertain at this time. References: Bersano A et al. Transthyretin Asn90 variant: amyloidogenic or non-amyloidogenic role. J Neurol Sci. 2009 Sep 15;284(1-2):113-5. Jimenez-Zepeda VH et al. A novel transthyretin variant p.H110D (H90D) as a cause of familial amyloid polyneuropathy in a large Irish kindred. Amyloid. 2015 Mar;22(1):26-30. Rowczenio D et al. Analysis of the TTR gene in the investigation of amyloidosis: A 25-year single UK center experience. Hum Mutat. 2019 Jan;40(1):90-96. Skare J et al. Two transthyretin mutations (glu42gly, his90asn) in an Italian family with amyloidosis. Clin Genet. 1994 Jun;45(6):281-4.
Illumina Clinical Services Laboratory,Illumina RCV000014369 SCV001280820 uncertain significance Amyloidogenic transthyretin amyloidosis 2017-04-28 criteria provided, single submitter clinical testing This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance.
Molecular Genetics Laboratory,London Health Sciences Centre RCV001173306 SCV001336390 likely benign Charcot-Marie-Tooth disease criteria provided, single submitter clinical testing
OMIM RCV000014369 SCV000034618 pathogenic Amyloidogenic transthyretin amyloidosis 1992-07-01 no assertion criteria provided literature only
Integrated Genetics/Laboratory Corporation of America RCV000014369 SCV000053247 benign Amyloidogenic transthyretin amyloidosis 2015-05-14 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.